Breaking News, Collaborations & Alliances

Pacira BioSciences to Acquire Flexion

Expands its leadership position in non-opioid pain management with Flexion’s lead product ZILRETTA.

Author Image

By: Charlie Sternberg

Associate Editor

Pacira BioSciences Inc. and Flexion Therapeutics Inc. have announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. The CVR is payable (subject to certain terms and conditions) in the event certain sales and/or regulatory milestones are achieved. The transaction was unanimously approved by the board of directors of each of Pacira and Flexion.   Flexion is ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters